ClinicalTrials.gg
TerminatedNCT00124748TOPSUpdated Feb 3, 2012Results posted

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

A Phase 3 interventional study of Imatinib mesylate in Leukemia, Myeloid, Chronic Phase, sponsored by Novartis Pharmaceuticals. Terminated at 75 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-02-03.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
This study was prematurely discontinued because no improvement was observed in the 800mg dose compared to 400mg dose

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
476
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase — none open to participants now, none under way, none of them phase 3. imatinib · Leukemia, Myeloid, Chronic-Phase.

Enrollment
2nd of 24
476 · median 56
Started
2005
with 2 others
Phase 3
5 of 30
none open now
Registered
19th of 30
by date
Lead sponsor
2 of 30
Novartis Pharmaceuticals

Among the 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2005, is one of 5 in phase 3, and was the 19th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

None of the 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase is open now. The open studies under Leukemia, Myeloid, Chronic-Phase, anywhere →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 30 studies testing imatinib in Leukemia, Myeloid, Chronic-Phase as a file.
02

Study summary

This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints.

03

Conditions studied

  • Leukemia, Myeloid, Chronic Phase

Keywords

  • CML
  • Philadelphia positive
  • Bcr-abl
  • imatinib mesylate
  • Chronic myeloid leukemia (CML) in chronic phase
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients within 6 months of diagnosis (date of initial diagnosis is the date of first cytogenetic analysis)
  • Diagnosis of chronic myelogenous leukemia (CML) in chronic phase with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations and presence of Breakpoint cluster region gene-abelson proto-oncogene (Bcr-Abl)
  • Documented chronic phase CML
  • Adequate end organ function as defined by:

    • total \< 1.5 x (ULN)
    • Serum glutamic oxaloacetic transaminase () and serum glutamate pyruvate transaminase (SGPT) \< 2.5 x ULN
    • creatinine \< 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  • Patients in late chronic phase, accelerated phase, or blastic phase are excluded
  • Patients who have received other agents
  • Patients who received Gleevec/Glivec for any duration prior to study entry, with the exception of those patients successfully completing [CSTI571A2107 (NCT00428909)] study immediately prior to the participation in this study
  • Patient received any treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide
  • Patients with another primary except if the other primary malignancy is neither currently or requiring active intervention
  • Patients who are: (a) pregnant, (b) breast feeding, (c) of without a negative pregnancy test prior to baseline and (d) male or female of childbearing potential unwilling to use barrier precautions throughout the trial ( women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).
  • Patient with a severe or uncontrolled medical condition (i.e., uncontrolled diabetes,chronic renal disease)
  • Patient previously received radiotherapy to ≥ 25% of the bone marrow
  • Patient had major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery
  • Patients with an (ECOG) Performance Status Score ≥ 3
  • Patients with (INR) or partial thromboplastin time (PTT) > 1.5 x , with the exception of patients on treatment with oral anticoagulants
  • Patients with known positivity for (HIV); baseline testing for HIV is not required
  • Patients with identified sibling donors where bone marrow transplant is elected as treatment

Other protocol-defined inclusion/exclusion criteria applied.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
476 participants (actual)

Study arms

  • Experimental
    Imatinib 400 mg

    Oral dose of 400mg Imatinib once daily. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted, reduced, or escalated based on guidelines defined in protocol.

    Drug: Imatinib mesylate

  • Experimental
    imatinib 800 mg

    Patients randomized to receive 800 mg Imatinib were to receive 400 mg twice daily (b.i.d.) oral administration, in the morning and the evening. All patients received the assigned dose starting on Day 0 (Visit 3). The dose of Imatinib could be interrupted or reduced based on guidelines defined in protocol.

    Drug: Imatinib mesylate

Interventions

  • Imatinib is packaged in bottles as 100mg and 400mg tablets

    Also known as: STI571, Gleevec, Glivec

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months

    MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).

    Time frame: 12 months

Secondary outcomes

  1. Percentage of Participants With Major Molecular Response (MMR) Rates at 24, 36, and 42 Months

    MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).

    Time frame: 24, 36 and 42 months

  2. Percentage of Participants With Complete Cytogenetic Response (CCyR) Rate at 12, 24, 36, 42 Months

    Cytogenetic response (CyR)is the percentage of Philadelphia chromosome positive metaphases (among at least 20 metaphase cells in bone marrow (BM)) with Complete Cytogenetic Response (CCyR) being 0 percent.

    Time frame: 12, 24, 36, 42 months

  3. Percentage of Participants With Complete Hematological Response (CHR) Rates at 12, 24, 36, and 42 Months

    Complete Hematologic Response (CHR) is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement.

    Time frame: 12, 24, 36, and 42 months

  4. Percentage of Patients With Undetectable Levels of Bcr-Abl (A Fusion Gene of the Breakpoint Cluster Region [Bcr] Gene and Abelson Proto-oncogene [Abl] Genes) Transcripts

    "Undetectable levels" or Complete molecular response is defined as Bcr-Abl ratio (%) on international scale (IS) \<= 0.0032% (≥ 4.5 log reduction of BCR-Abl transcripts from a standardized baseline).

    Time frame: 12 , 24, 36 and 42 months

  5. Time to First Major Molecular Response

    MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally). Time to MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375. Time to first MMR was evaluated using the Kaplan-Meier method

    Time frame: 42 months overall

  6. Time to First Complete Cytogenetic Response

    Cytogenetic response (CyR) is the percentage of Philadelphia positive metaphases (among at least 20 metaphase cells in Bone Marrow) with Complete Cytogenetic Response (CCyR) being 0 percent. Time to CCyR (months) = (date of first CCyR or censoring - date of randomization + 1) / 30.4375. Time to first CCyR was evaluated using the Kaplan-Meier method.

    Time frame: 60 months overall

  7. Time to First Complete Hematological Response (CHR)]

    Complete Hematological Response (CHR) is defined is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement. Time to CHR (months) = (date of first CHR or censoring - date of randomization + 1) / 30.4375. Time to first CHR was evaluated using the Kaplan-Meier method.

    Time frame: 60 months overall

  8. Estimated Rate of Event Free Survival (EFS) in Two Treatment Arms

    EFS on treatment was defined as time between randomization and either (1) death due to any cause during study treatment, (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment, (3) loss of complete hematological response (CHR), or (4) loss of major cytogenic response (MCyR) while on treatment. Estimated rate of EFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

    Time frame: 60 months over all

  9. Estimated Rate of Progression Free Survival (PFS) in Two Treatment Arms

    PFS on study which was defined as time between randomization and either (1) death due to any cause on treatment of during follow-up after discontinuation of treatment or (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment during follow-up after discontinuation of study treatment. Estimated rate of PFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

    Time frame: 60 months over all and follow up period

  10. Estimated Rate of Progression to Accelerated Phase (AC)/Blast Crisis (BC) in Two Treatment Arms

    (Accelerated Phase/Blast Crisis) AP/BC was defined as time between randomization and either (1) (Chronic Myeloid Leukemia) CML-related death (if death was primary reason for discontinuation) or (2) progression to AP or BC (during treatment). Estimated rate of AC/BC was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

    Time frame: 60 months over all and follow up period

  11. Estimated Rate of Overall Survival (OS) in Two Treatment Arms

    OS was defined as time between randomization and death due to any cause during study treatment or during follow-up after discontinuation of treatment. Estimated rate of OS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

    Time frame: 60 months over all and follow up period

  12. Kaplan-Meier Estimates of Duration of First Major Molecular Response Until Confirmed Loss

    Duration of MMR (months) = (date of first confirmed loss or censoring - date of MMR + 1 ) / 30.4375. Estimated rate of duration of first MMR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

    Time frame: From First major molecular response to first confirmed loss or censoring

  13. Kaplan-Meier Estimates of Duration of First Complete Cytogenetic Response (CCyR)

    Duration of CCyR was defined as the time between date of CCyR and the earliest of either (1) loss of CCyR OR (2) (Chronic Myeloid Leukemia) CML-related death or progression to (Accelerated Phase/Blast Crisis) AP/BC during study treatment. Estimated rate of duration of first CCyR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

    Time frame: From first complete cytogenetic response to first confirmed loss or censoring

  14. Mean Actual Dose Intensity Per Day

    The mean actual dose intensity per day from start of treatment up to last dose or discontinuation was evaluated up to Month 36. Actual dose intensity (mg/day) = total dose/time on treatment (periods of zero dose are included)

    Time frame: start of treatment to Month 36

  15. Imatinib Pharmacokinetic Trough Plasma Concentration (Cmin) at Month 12

    Imatinib PK trough plasma concentration (Cmin) was defined as any pre-dose Imatinib plasma concentration

    Time frame: Month 12

  16. Estimated Rates of Progression Free Survival (PFS) on Treatment by Major Molecular Response (MMR)

    A Landmark Kaplan-Meier analysis was performed for PFS at 42 months by MMR status at 6, 12, and 18 months to investigate their prognostic value.

    Time frame: 42 months

  17. Time to First Complete Molecular Response (CMR)]

    Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.

    Time frame: 48 months overall

  18. Number of Participants With the Effect of Imatinib on the Diabetic Participants With Known Concomitant Type II Diabetes

    Time frame: 12 months

07

Results

Posted Feb 3, 2012

Participant flow

Participant flow — Overall Study
MilestoneImatinib 400 mgImatinib 800 mg
Started157319
Safety population157316
Completed1435
Not completed143284
Withdrew: Adverse event839
Withdrew: Abnormal laboratory value22
Withdrew: Abnormal procedure01
Withdrew: Lack of efficacy2041
Withdrew: No longer requires study drug11
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject515
Withdrew: Lost to follow-up27
Withdrew: Administrative problem(study terminated)101174
Withdrew: Death13

Outcome measures

PrimaryPercentage of Participants With Major Molecular Response (MMR) Rates at 12 Months

MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).

Time frame:
12 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months
Percentage of participantsImatinib 400 mgImatinib 800 mg
Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months38.945.1
SecondaryPercentage of Participants With Major Molecular Response (MMR) Rates at 24, 36, and 42 Months

MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally).

Time frame:
24, 36 and 42 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Molecular Response (MMR) Rates at 24, 36, and 42 Months
Percentage of participantsImatinib 400 mgImatinib 800 mg
24 months53.550.8
36 months52.249.8
42 months51.650.2
SecondaryPercentage of Participants With Complete Cytogenetic Response (CCyR) Rate at 12, 24, 36, 42 Months

Cytogenetic response (CyR)is the percentage of Philadelphia chromosome positive metaphases (among at least 20 metaphase cells in bone marrow (BM)) with Complete Cytogenetic Response (CCyR) being 0 percent.

Time frame:
12, 24, 36, 42 months
Reported as:
Number · Percentage of Participants
Percentage of Participants With Complete Cytogenetic Response (CCyR) Rate at 12, 24, 36, 42 Months
Percentage of ParticipantsImatinib 400 mgImatinib 800 mg
12 months66.970.2
24 months76.476.8
36 months79.080.6
42 months80.381.5
SecondaryPercentage of Participants With Complete Hematological Response (CHR) Rates at 12, 24, 36, and 42 Months

Complete Hematologic Response (CHR) is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement.

Time frame:
12, 24, 36, and 42 months
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Hematological Response (CHR) Rates at 12, 24, 36, and 42 Months
Percentage of participantsImatinib 400 mgImatinib 800 mg
12 months94.993.7
24 months94.993.7
36 months96.294.4
42 months96.294.4
SecondaryPercentage of Patients With Undetectable Levels of Bcr-Abl (A Fusion Gene of the Breakpoint Cluster Region [Bcr] Gene and Abelson Proto-oncogene [Abl] Genes) Transcripts

"Undetectable levels" or Complete molecular response is defined as Bcr-Abl ratio (%) on international scale (IS) \<= 0.0032% (≥ 4.5 log reduction of BCR-Abl transcripts from a standardized baseline).

Time frame:
12 , 24, 36 and 42 months
Reported as:
Number · Percentage of Partcipants
Percentage of Patients With Undetectable Levels of Bcr-Abl (A Fusion Gene of the Breakpoint Cluster Region [Bcr] Gene and Abelson Proto-oncogene [Abl] Genes) Transcripts
Percentage of PartcipantsImatinib 400 mgImatinib 800 mg
12 Months4.54.7
24 Months11.510.3
36 Months12.713.2
42 Months14.612.5
SecondaryTime to First Major Molecular Response

MMR is defined as Bcr-Abl (A fusion gene of the breakpoint cluster region \[Bcr\] gene and Abelson proto-oncogene \[Abl\] genes) transcript ratio ≤0.1% (≥ 3 log reduction of BCR-ABL transcripts from a standardized baseline), as detected by reverse transcriptase polymerase chain reaction \[RT-PCR\] (performed centrally). Time to MMR (months) = (date of first MMR or censoring - date of randomization + 1) / 30.4375. Time to first MMR was evaluated using the Kaplan-Meier method

Time frame:
42 months overall
Reported as:
Median · Months
Time to First Major Molecular Response
MonthsImatinib 400 mgImatinib 800 mg
Time to First Major Molecular Response13.6 (10.8 to 15.6)8.4 (8.3 to 9.0)
SecondaryTime to First Complete Cytogenetic Response

Cytogenetic response (CyR) is the percentage of Philadelphia positive metaphases (among at least 20 metaphase cells in Bone Marrow) with Complete Cytogenetic Response (CCyR) being 0 percent. Time to CCyR (months) = (date of first CCyR or censoring - date of randomization + 1) / 30.4375. Time to first CCyR was evaluated using the Kaplan-Meier method.

Time frame:
60 months overall
Reported as:
Median · Months
Time to First Complete Cytogenetic Response
MonthsImatinib 400 mgImatinib 800 mg
Time to First Complete Cytogenetic Response10.8 (5.9 to 11.2)5.8 (5.8 to 6.0)
SecondaryTime to First Complete Hematological Response (CHR)]

Complete Hematological Response (CHR) is defined is where all of the following criteria must be present for ≥4 weeks: White Blood Cell (WBC) count \<10 x 109/L, Platelet count \<450 x 109/L, Basophils \<5%, No blasts and promyelocytes in Peripheral Blood (PB), (Myelocytes + metamyelocytes) \< 5% in PB and No evidence of extramedullary involvement. Time to CHR (months) = (date of first CHR or censoring - date of randomization + 1) / 30.4375. Time to first CHR was evaluated using the Kaplan-Meier method.

Time frame:
60 months overall
Reported as:
Median · Months
Time to First Complete Hematological Response (CHR)]
MonthsImatinib 400 mgImatinib 800 mg
Time to First Complete Hematological Response (CHR)]1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
SecondaryEstimated Rate of Event Free Survival (EFS) in Two Treatment Arms

EFS on treatment was defined as time between randomization and either (1) death due to any cause during study treatment, (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment, (3) loss of complete hematological response (CHR), or (4) loss of major cytogenic response (MCyR) while on treatment. Estimated rate of EFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

Time frame:
60 months over all
Reported as:
Number · Percent probability
Estimated Rate of Event Free Survival (EFS) in Two Treatment Arms
Percent probabilityImatinib 400 mgImatinib 800 mg
12 Months95.3 (90.5 to 97.7)98.0 (95.6 to 99.1)
24 Months94.6 (89.5 to 97.3)95.3 (92.1 to 97.3)
36 Months92.3 (86.5 to 95.7)94.5 (91.1 to 96.7)
42 Months92.3 (86.5 to 95.7)94.1 (90.5 to 96.3)
48 Months92.3 (86.5 to 95.7)93.6 (89.9 to 96.0)
60 Months90.3 (82.7 to 94.7)93.6 (89.9 to 96.0)
SecondaryEstimated Rate of Progression Free Survival (PFS) in Two Treatment Arms

PFS on study which was defined as time between randomization and either (1) death due to any cause on treatment of during follow-up after discontinuation of treatment or (2) progression to accelerated phase (AP) or blast crisis (BC) on treatment during follow-up after discontinuation of study treatment. Estimated rate of PFS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

Time frame:
60 months over all and follow up period
Reported as:
Number · Percent probability
Estimated Rate of Progression Free Survival (PFS) in Two Treatment Arms
Percent probabilityImatinib 400 mgImatinib 800 mg
12 Months97.4 (93.2 to 99.0)98.7 (96.5 to 99.5)
24 Months95.9 (91.2 to 98.2)97.5 (94.9 to 98.8)
36 Months94.4 (89.0 to 97.1)96.7 (93.7 to 98.3)
42 Months94.4 (89.0 to 97.1)96.3 (93.2 to 98.0)
48 Months94.4 (89.0 to 97.1)95.8 (92.5 to 97.7)
60 Months94.4 (89.0 to 97.1)95.8 (92.5 to 97.7)
SecondaryEstimated Rate of Progression to Accelerated Phase (AC)/Blast Crisis (BC) in Two Treatment Arms

(Accelerated Phase/Blast Crisis) AP/BC was defined as time between randomization and either (1) (Chronic Myeloid Leukemia) CML-related death (if death was primary reason for discontinuation) or (2) progression to AP or BC (during treatment). Estimated rate of AC/BC was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

Time frame:
60 months over all and follow up period
Reported as:
Number · Percent probability
Estimated Rate of Progression to Accelerated Phase (AC)/Blast Crisis (BC) in Two Treatment Arms
Percent probabilityImatinib 400 mgImatinib 800 mg
12 Months97.4 (93.2 to 99.0)99.0 (97.0 to 99.7)
24 Months95.9 (91.2 to 98.2)97.9 (95.3 to 99.0)
36 Months95.2 (90.1 to 97.7)97.5 (94.7 to 98.8)
42 Months95.2 (90.1 to 97.7)97.0 (94.1 to 98.5)
48 Months95.2 (90.1 to 97.7)97.0 (94.1 to 98.5)
60 Months95.2 (90.1 to 97.7)97.0 (94.1 to 98.5)
SecondaryEstimated Rate of Overall Survival (OS) in Two Treatment Arms

OS was defined as time between randomization and death due to any cause during study treatment or during follow-up after discontinuation of treatment. Estimated rate of OS was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

Time frame:
60 months over all and follow up period
Reported as:
Number · Percent probability
Estimated Rate of Overall Survival (OS) in Two Treatment Arms
Percent probabilityImatinib 400 mgImatinib 800 mg
12 Months98.7 (94.9 to 99.7)99.0 (97.1 to 99.7)
24 Months97.4 (93.2 to 99.0)97.8 (95.4 to 98.9)
36 Months96.1 (91.4 to 98.2)95.5 (92.5 to 97.3)
42 Months94.7 (89.7 to 97.2)94.8 (91.6 to 96.8)
48 Months94.0 (88.7 to 96.8)93.4 (89.7 to 95.8)
60 Months94.0 (88.7 to 96.8)93.4 (89.7 to 95.8)
SecondaryKaplan-Meier Estimates of Duration of First Major Molecular Response Until Confirmed Loss

Duration of MMR (months) = (date of first confirmed loss or censoring - date of MMR + 1 ) / 30.4375. Estimated rate of duration of first MMR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

Time frame:
From First major molecular response to first confirmed loss or censoring
Reported as:
Number · Percent probability
Kaplan-Meier Estimates of Duration of First Major Molecular Response Until Confirmed Loss
Percent probabilityImatinib 400 mgImatinib 800 mg
3 Months100 (100 to 100)96.3 (92.9 to 98.0)
6 Months98.3 (93.3 to 99.6)90.7 (86.2 to 93.8)
9 Months97.4 (92.2 to 99.2)90.2 (85.7 to 93.4)
12 Months95.6 (89.8 to 98.2)88.4 (83.6 to 91.9)
15 Months93.8 (87.4 to 97.0)87.5 (82.5 to 91.2)
18 Months92.8 (86.2 to 96.4)86.1 (80.9 to 90.0)
21 Months90.9 (83.8 to 95.0)85.1 (79.8 to 89.1)
24 Months89.9 (82.5 to 94.3)83.6 (78.0 to 87.8)
30 Months88.5 (80.5 to 93.4)82.5 (76.8 to 86.9)
36 Months85.1 (75.6 to 91.1)81.1 (75.1 to 85.8)
42 Months85.1 (75.6 to 91.1)77.9 (70.4 to 83.8)
SecondaryKaplan-Meier Estimates of Duration of First Complete Cytogenetic Response (CCyR)

Duration of CCyR was defined as the time between date of CCyR and the earliest of either (1) loss of CCyR OR (2) (Chronic Myeloid Leukemia) CML-related death or progression to (Accelerated Phase/Blast Crisis) AP/BC during study treatment. Estimated rate of duration of first CCyR was analyzed by Kaplan-Meier estimate (percent probability and 95% Confidence interval).

Time frame:
From first complete cytogenetic response to first confirmed loss or censoring
Reported as:
Number · Percent probability
Kaplan-Meier Estimates of Duration of First Complete Cytogenetic Response (CCyR)
Percent probabilityImatinib 400 mgImatinib 800 mg
6 Months99.1 (94.0 to 99.9)99.2 (96.7 to 99.8)
12 Months98.2 (93.1 to 99.6)97.8 (94.7 to 99.1)
18 Months98.2 (93.1 to 99.6)97.3 (94.1 to 98.8)
24 Months98.2 (93.1 to 99.6)96.8 (93.3 to 98.4)
30 Months98.2 (93.1 to 99.6)96.8 (93.3 to 98.4)
36 Months98.2 (93.1 to 99.6)95.9 (91.9 to 98.0)
42 Months98.2 (93.1 to 99.6)95.9 (91.9 to 98.0)
SecondaryMean Actual Dose Intensity Per Day

The mean actual dose intensity per day from start of treatment up to last dose or discontinuation was evaluated up to Month 36. Actual dose intensity (mg/day) = total dose/time on treatment (periods of zero dose are included)

Time frame:
start of treatment to Month 36
Reported as:
Mean · mg/day
Mean Actual Dose Intensity Per Day
mg/dayImatinib 400 mgImatinib 800 mg
Mean Actual Dose Intensity Per Day399.3 ± 83.84643.3 ± 158.63
SecondaryImatinib Pharmacokinetic Trough Plasma Concentration (Cmin) at Month 12

Imatinib PK trough plasma concentration (Cmin) was defined as any pre-dose Imatinib plasma concentration

Time frame:
Month 12
Reported as:
Mean · mg/mL
Imatinib Pharmacokinetic Trough Plasma Concentration (Cmin) at Month 12
mg/mLImatinib 400 mgImatinib 800 mg
Imatinib Pharmacokinetic Trough Plasma Concentration (Cmin) at Month 121458.2 ± 2259.5739.58 ± 1321.09
SecondaryEstimated Rates of Progression Free Survival (PFS) on Treatment by Major Molecular Response (MMR)

A Landmark Kaplan-Meier analysis was performed for PFS at 42 months by MMR status at 6, 12, and 18 months to investigate their prognostic value.

Time frame:
42 months
Reported as:
Number · Percent probability
Estimated Rates of Progression Free Survival (PFS) on Treatment by Major Molecular Response (MMR)
Percent probabilityImatinib 400 mgImatinib 800 mg
No MMR at 6 Months94.8 (88.0 to 97.8)95.6 (90.3 to 98.0)
MMR at 6 Months100 (100 to 100)99.0 (93.2 to 99.9)
No MMR at 12 Months93.2 (82.9 to 97.4)94.6 (87.4 to 97.7)
MMR at 12 Months100 (100 to 100)99.3 (95.0 to 99.9)
No MMR at 18 Months96.7 (78.6 to 99.5)97.0 (88.6 to 99.3)
MMR at 18 Months98.7 (91.2 to 99.8)99.3 (95.2 to 99.9)
SecondaryTime to First Complete Molecular Response (CMR)]

Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.

Time frame:
48 months overall
Reported as:
Median · Months

No measurements were reported for this outcome.

SecondaryNumber of Participants With the Effect of Imatinib on the Diabetic Participants With Known Concomitant Type II Diabetes
Time frame:
12 months
Reported as:
Number · Participants

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib 400mg—42/157 (26.8%)157/157 (100%)
Imatinib 800mg—121/316 (38.3%)315/316 (99.7%)
Most frequent serious events
Showing 10 of 221
Most frequent serious events
EventImatinib 400mgImatinib 800mg
PyrexiaGeneral disorders3/15713/316
NeutropeniaBlood and lymphatic system disorders5/15712/316
ThrombocytopeniaBlood and lymphatic system disorders4/1579/316
AnaemiaBlood and lymphatic system disorders3/1576/316
Febrile neutropeniaBlood and lymphatic system disorders2/1575/316
AppendicitisInfections and infestations0/1575/316
GastroenteritisInfections and infestations2/1575/316
PneumoniaInfections and infestations2/1575/316
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1575/316
Angina pectorisCardiac disorders2/1570/316
Most frequent other events
Showing 10 of 80
Most frequent other events
EventImatinib 400mgImatinib 800mg
NauseaGastrointestinal disorders78/157205/316
DiarrhoeaGastrointestinal disorders71/157184/316
Muscle spasmsMusculoskeletal and connective tissue disorders69/157141/316
VomitingGastrointestinal disorders54/157140/316
Oedema peripheralGeneral disorders43/157135/316
Periorbital oedemaEye disorders46/157132/316
FatigueGeneral disorders51/157131/316
AnaemiaBlood and lymphatic system disorders41/157120/316
RashSkin and subcutaneous tissue disorders32/157119/316
ThrombocytopeniaBlood and lymphatic system disorders36/157111/316

Baseline characteristics

Age Continuous
Age Continuous(years)Imatinib 400 mgImatinib 800 mgTotal
Mean46.2 ± 14.9048.2 ± 13.8947.6 ± 14.25
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib 400 mgImatinib 800 mgTotal
Female73136209
Male84183267
08

Study locations

75 sites
  • University of South Alabama
    Mobile, Alabama 36693, United States
  • Alta Bates Comprehsenive Cancer Center
    Berkeley, California 94704, United States
  • University of Miami
    Berkeley, California 94704, United States
  • South Bay Oncology Hematology Partners
    Campbell, California 95008, United States
  • UCLA Medical Center
    Los Angeles, California 90095, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Osler Medical Inc.
    Melbourne, Florida 32901, United States
  • Advanced Medical Specialists
    Miami, Florida 33176, United States
  • Integrated Community Oncology Network
    Orange Park, Florida 32073, United States
  • Hematology-Oncology Associates, P.A.
    Pensacola, Florida 32501, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 233401, United States
  • Palm Beach Cancer Institute
    West Palm Beach, Florida 33401, United States
  • Cancer Research Center of Hawaii
    Honolulu, Hawaii 96813, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana Blood and Marrow Institutw
    Beech Grove, Indiana 46107, United States
  • Indiana Blood and Marrow Transplant
    Beech Grove, Indiana 46107, United States
  • University of Iowa Hospitals & Clinic
    Iowa City, Iowa 52242, United States
  • University of Kentucky - C201 Clinic
    Lexington, Kentucky 40536, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Lousville Oncology, Clinical Research Program M-25
    Louisville, Kentucky 40202, United States
  • Jayne S. Gurtler, MD, Laura A. Brinz, MD & Angelo Russo, MD
    Metairie, Louisiana 70006, United States
  • Hematology and Oncology Specialists
    New Orleans, Louisiana 70115, United States
  • LSU Health Science Center
    Shreveport, Louisiana 71103, United States
  • LSU Health Scine Center
    Shreveport, Louisiana 71130, United States
  • St. Agnes Hospital
    Baltimore, Maryland 21229, United States
  • Great Lakes Cancer Institute
    Lansing, Michigan 48910, United States
  • U of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • San Juan Oncology Associates
    Farmington, New Mexico 87401, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Cancer Center of the Carolinas
    Greenville, North Carolina 29615, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • University Hospitals of Cleveland, Case Comprehensive Cancer Center
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Kaiser Permanente Northwest Region Oncology/Hemacology
    Portland, Oregon 97227, United States
  • Kaiser Permanente Northwest Region
    Portland, Oregon 97227, United States
  • Western Pennsylvania Hospital
    Pittsburgh, Pennsylvania 15224, United States
  • University of Pittsburg, Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • MUSC Hollings Cancer Center
    Charleston, South Carolina 29425, United States
  • Cancer Center of the Carolinas
    Greenville, South Carolina 29615, United States
  • Cancer Centers of the Carolinas
    Greenville, South Carolina 29615, United States
  • The Jones Clinic
    Germantown, Tennessee 38138, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • UT Southwestern Harold C. Simmons Comprehensive Cancer Center
    Dallas, Texas 75390, United States
  • University of Texas / MD Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • University of Virgina Cancer Center, UVA Division of Hematology & Oncology
    Charlottesville, Virginia 22908, United States
  • Novartis Investigative Site
    Buenos Aires, Argentina
  • Novartis Investigative Site
    La Plata, Argentina
  • Novartis Investigative Site
    St. Leonards, New South Wales, Australia
  • Novartis Investigative Site
    Waratah, New South Wales, Australia
  • Novartis Investigative Site
    Westmead, New South Wales, Australia
  • Novartis Investigative Site
    Herston, Queensland, Australia
  • Novartis Investigative Site
    Woolloongabba, Queensland, Australia
  • Novartis Investigative Site
    Adelaide, South Australia, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria, Australia
  • Novartis Investigative Site
    Fitzroy, Victoria, Australia
  • Novartis Investigative Site
    Frankston, Victoria, Australia
  • Novartis Investigative Site
    Parkville, Victoria, Australia
  • Novartis Investigative Site
    Prahran, Victoria, Australia
  • Novartis Investigative Site
    South Brisbane, Australia
  • Novartis Investigative Site
    Campinas, Brazil
  • Novartis Investigative Site
    Calgary, Canada
  • Novartis Investigative Site
    Montreal, Canada
  • Novartis Investigative Site
    Ottawa, Canada
  • Novartis Investigative Site
    Quebec, Canada
  • Novartis Investigative Site
    Bologna, Italy
  • Novartis Investigative Site
    Firenze, Italy
  • Novartis Investigative Site
    Milano, Italy
  • Novartis Investigative Site
    Napoli, Italy
  • Novartis Investigative Site
    Orbassano, Italy
  • Novartis Investigative Site
    Roma, Italy
09

References and documents

Publications

  • Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23. PubMed 24859364 ↗
  • Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, Hughes TP. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013 May 9;121(19):3818-24. doi: 10.1182/blood-2012-10-462291. Epub 2013 Mar 20. PubMed 23515925 ↗
  • Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 2012 May;97(5):731-8. doi: 10.3324/haematol.2011.045666. Epub 2012 Feb 7. PubMed 22315495 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2005
First posted
Jul 28, 2005
Start
Jun 2005
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Feb 3, 2012
Last update
Feb 3, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00124748
Responsible party
Sponsor
First posted
Jul 28, 2005
Start date
Jun 2005
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Feb 3, 2012
Last update
Feb 3, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion